Maine Journal - May 2021

More documents

Recommendations

Info

Page 4 ANA Maine Journal May, June, July 2021 What you need to know about the coronavirus variants Marisa Iati and Angela Fritz **This article is reprinted with permission from the authors and The Washington Post. Viruses are always mutating and taking on new forms. The coronavirus has thousands of variants that have been identified. But several, including variants first found in the United Kingdom, South Africa and Brazil, are highly transmissible and have sparked concerns that vaccines may be less effective against them. The same protective measures that have warded off the virus throughout the pandemic — maintaining social distance, wearing masks and washing our hands — are even more critical in the face of more transmissible variants. The New York variant (B.1.526) Where and when was it discovered? This variant, which was found in samples obtained as early as November, probably emerged in the Washington Heights section of New York, Fauci told reporters in March. By the middle of that month, this variant made up nearly half of the city’s new infections. Where is it now? Officials have reported this variant in at least 14 other states, including Texas, Wyoming and Maryland, Bloomberg reported. What makes it different? Some scientists are concerned that this variant may be more transmissible than previous versions. Scott Gottlieb, former director of the Food and Drug Administration, expressed worry that a mutation on this variant could enable it to reinfect people who have already had the virus. Will vaccines work? This variant seems to have some resistance to existing vaccines, although not as much as the variant first detected in South Africa, Fauci said on CBS News’s “Face the Nation.” Gottlieb said he was also concerned that this variant could partly elude the effects of vaccination. Related After weeks of declining cases, echoes of hot spots emerge in Upper Midwest, New York City area Registered Nurses (OB-GYN) Full-Time Nights Northern Light Mayo Hospital is currently seeking a Registered Nurse in our Obstetrics Unit for 36 hours per week. This position will be for 7:00 p.m. – 7:00 a.m. Please apply online at www.northernlighthealth.org, and/or E-mail resume to nkusnierz@northernlight.org. The South Africa variant (B.1.351) Where and when was it discovered? This mutation, also referred to as 501Y.V2, was found in South Africa in early October and announced in December, when the country’s health minister said the strain seemed to affect young people more than previous strains. This variant may have contributed to a surge of infections and hospitalizations across South Africa. Where is it? This mutation has been identified in at least four dozen countries. On Jan. 28, South Carolina officials announced that this variant had affected two people there with no travel history — the first instances of this strain identified in the United States. It has since been found in more than two dozen other states. What makes it different? This mutation shares some similarities to the variant first identified in the U.K. and, like that strain, appears to be more transmissible. There is no evidence that it is more lethal. Gottlieb has suggested that this variant might be more resistant to antibody therapies. There is some evidence that this variant could allow for reinfection: A man in France was in critical condition in mid-February after being infected with this strain four months after he was previously infected with the virus. Will vaccines work? The vaccines may have a diminished impact against this variant, but they probably will still be effective, top infectious-diseases expert Anthony S. Fauci said in January. Moderna has said its vaccine protects against the variant first identified in South Africa, with an important caveat: The vaccine-elicited antibodies were also less effective at neutralizing this mutation in a laboratory dish. Pfizer and BioNTech released their own study, not yet peer-reviewed, that suggests their vaccine effectively neutralizes this variant, though was slightly less effective. On Jan. 29, Johnson & Johnson said its single-shot vaccine was robustly effective in a massive global trial, but that its protection against sickness was weaker in South Africa. Biotechnology company Novavax has also indicated that its vaccine was significantly less effective during a trial in South Africa. In South Africa, the distribution of the Oxford- AstraZeneca vaccine has been halted. The vaccine did not provide sufficient protection against mild and moderate cases caused by a new variant, health officials said. Related First known patient reinfected with South Africa coronavirus variant is in critical condition South Africa suspends Oxford-AstraZeneca vaccine rollout after researchers report ‘minimal’ protection against coronavirus variant Mutated virus may reinfect people already stricken once with covid-19, sparking debate and concerns Coronavirus variant identified in South Africa seen for first time in United States U.K. variant (B.1.1.7) Where and when was it discovered? This variant was first found in the United Kingdom, specifically in London and the nearby county of Kent, in September. It is sometimes referred to as the Millinocket Regional Hospital, a Critical Access Hospital nestled at the base of Mt. Katahdin and Baxter State Park, has immediate openings for the following positions: $5,000 SIGN-ON BONUS FOR FULL TIME POSITIONS!!! Emergency Department RN Positions Available: FULL TIME- NIGHT SHIFT PART TIME- NIGHT SHIFT Inpatient Unit RN Positions Available: FULL TIME SCU- NIGHT SHIFT FULL TIME- DAY SHIFT *FULL TIME NURSING SUPERVISOR NEEDED FOR NIGHT SHIFT* Qualified applicants please apply online at www.mrhme.org/careers MILLINOCKET REGIONAL HOSPITAL - 200 Somerset Street, Millinocket, Maine 04462 (207) 723-7275 | www.mrhme.org E.O.E. Access to Excellence in Healthcare “Kent” variant. It has been spreading rapidly in Britain, Denmark and Ireland since December. Where is it? Dozens of countries, including the United States, have seen infections from this variant of the virus. It is by far the most prevalent variant of concern in the United States, with thousands of cases across the country. The Centers for Disease Control and Prevention released a model forecast in early January that indicated the variant could become the dominant strain in the United States by some point in March. A recent study showed this variant was spreading rapidly in the United States by early February. What makes it different? The variant first identified in the U.K. appears more transmissible than the more common strain. Preliminary data also suggests that this strain may be 30 to 70 percent more lethal than previous mutations. Will vaccines work? The scientific consensus is that the vaccines will remain effective against this mutation because those inoculations provoke an array of neutralizing antibodies and other immune-system responses. Biotechnology companies Pfizer, Moderna and Novavax have said their vaccines appear to work against this variant. Ravindra Gupta, a professor of clinical microbiology at the University of Cambridge, found in a study of older adults that the immune response triggered by the Pfizer vaccine was modestly less effective against the variant first identified in the U.K. Related Virus variant first detected in the U.K. has been deadlier, study confirms U.K. coronavirus variant spreading rapidly through United States, study finds Denmark is sequencing all coronavirus samples and has an alarming view of the U.K. variant CDC warns highly transmissible coronavirus variant to become dominant in U.S. The ‘Eeek’ mutation (E484K) Where and when was it discovered? This might best be described as a mutation within a mutation. It’s called E484K — or “Eeek,” as epidemiologists refer to it — and it’s appearing on some of the variants we describe below. It’s not brand new; it has appeared many times since the start of the pandemic, but experts have been concerned about it. It gained mainstream attention when it started to coincide with other variants that are more contagious. Where is it? Eeek has been seen in the variants first discovered in the U.K., South Africa and Brazil. It has also been detected in more than 200 samples of the virus sequenced in the United States since May. What makes it different? The Eeek mutation changes the virus’s spike protein, which is what vaccines target. By itself, this mutation does not change the virus significantly. The concern with this mutation is when it’s paired with the other variants, which could help the virus evade detection and make neutralization by the human immune system less efficient. Will vaccines work? Scientists are actively trying to answer this question. Clinical trial data have indicated that vaccines were less effective in preventing infections with variants in South Africa featuring the mutation. But the vaccines still dramatically lowered the chance of severe illness or death. Semi-related to the vaccine question: One study found preliminary evidence that patients in South Africa who had survived an earlier bout with the more common coronavirus were becoming infected a second time — though not severely ill — after exposure to the variant with this mutation.
May, June, July 2021 ANA Maine Journal Page 5 Related Worrisome E484K coronavirus mutation seen in U.K. variant and in some U.S. samples Brazil variant (P. 1) Where and when was it discovered? Sequencing studies found the variant in Brazil, mainly in Rio de Janeiro, as early as July. Researchers in Japan discovered it in travelers from Brazil in January. Where is it now? It has been confirmed in more than two dozen countries, including Japan, Spain and New Zealand. On Jan. 25, Minnesota health officials confirmed the first U.S. case of this variant in a resident with recent travel history to Brazil. It has since been found in at least 18 states. What makes it different? The variant has more than a dozen alterations, several of which are found on the virus’s spike protein, which binds the virus to a cell. Because of that, researchers think the strain is probably more transmissible. There is also some early evidence that antibodies might not recognize the P.1 variant, which could lead to reinfection. Will vaccines work? There’s no strong evidence right now suggesting that vaccines won’t work against the variant first identified in Brazil. However, scientists have raised the possibility that this variant can evade antibodies, which would impact the current vaccines’ effectiveness. A study of the Pfizer-BioNTech vaccine published in March determined that it was highly effective at neutralizing the variant found in Brazil. Moderna has announced that it would develop a new vaccine tailored to a similar variant in case an updated shot becomes necessary. Related The Amazonian city that hatched the Brazil variant has been crushed by it First U.S. case of highly transmissible Brazil coronavirus variant identified in Minnesota The Denmark/California mutation (L452R) Where and when was it discovered? This mutation was detected in Denmark in March. Where is it now? A variant with this mutation was found in California this winter and became dominant there over five months, eventually making up more than half of infections in 44 of the state’s 58 counties. This mutation has also been confirmed in several other states. British officials identify coronavirus mutations, but significance remains unclear How can we protect ourselves from the variants? The same protective measures that have warded off the virus throughout the pandemic — maintaining social distance, wearing masks and washing our hands — are even more critical in the face of more transmissible variants. Those guidelines will simultaneously keep you from becoming ill from one of those variants, while making it harder for the virus to mutate in the first place. “Viruses don’t mutate unless they replicate,” Fauci said in January. But it’s also important for scientists to learn as much as they can about these variants, in case there are specific ways we can slow their spread. Until the research exists, we can’t make assumptions about what new variants will do. What do the variants mean for vaccines? “We need to get as many people vaccinated with the current vaccine that we have as we possibly can … and prepare for the potential eventuality that we might have to update this vaccine sometime in the future.” — Fauci in January As more significant variants are reported, the obvious (and arguably most important) question is whether the vaccines will work on them. Some of the mutations have sparked particular concern because they affect the spikes on the virus, which is what the vaccines target. In short, the pharmaceutical companies are testing new variants against their vaccines and spinning up new trials. Moderna and Pfizer-BioNTech can update their vaccines quickly because of their mRNA technology, which can be reprogrammed to target new variants. Pfizer and Moderna have run tests on the variants and while the vaccines still triggered a response, they appeared to be less effective. A growing number of scientists anticipate that we will eventually need something similar to the annual flu shot — companies will periodically update their vaccines to match the prevalent coronavirus variants, and we will need to get boosters to stay protected. “With flu, we need to adapt the vaccines. We can see that already,” said Ravindra Gupta, a professor of clinical microbiology at the University of Cambridge. “The companies do realize there is a problem in the longer term, and they will deal with it just as we have done with flu every year.” Related New coronavirus variants accelerate race to make sure vaccines keep up Joel Achenbach, William Booth, Carolyn Y. Johnson, Sarah Kaplan, Laurie McGinley and Fenit Nirappil contributed to this report. What makes it different? There is evidence that this mutation enhances the virus’s ability to bind to human receptor cells, making it more transmissible. Some scientists are urging public-health officials to declare the variant with this mutation circulating in California a “variant of concern,” which would make it the first homegrown variant with this label. Will vaccines work? Some scientists think this mutation might make the virus more resistant to vaccines because the mutation is in the spike protein, which enables the virus to attach to cells. But scientists also say that more study is needed before they can draw conclusions. Related New research shows California coronavirus variant is more transmissible Another coronavirus variant linked to growing share of cases, several large outbreaks, in California The original variant (D614G) Where and when was it discovered? This mutation, known to scientists simply as “G,” was discovered in China in January 2020. It soon spread through New York City and Europe. Where is it? The “G” mutation has become ubiquitous. By July, about 70 percent of the 50,000 genomes of the coronavirus uploaded by researchers worldwide to a shared database carried the variant. What makes it different? Some scientists think this mutation is significantly more transmissible than the original strain of the virus. That’s because this variant has four to five times more spikes on its surface. Those spikes enable the virus to latch onto and infect cells. But other scientists still contest the greater transmissibility. Will vaccines work? The G variant was the dominant strain when 2020 vaccine trials took place. The Pfizer and Moderna vaccines showed a 95 percent efficacy in trials. Related This coronavirus mutation has taken over the world. Scientists are trying to understand why. Massive genetic study shows coronavirus mutating and potentially evolving amid rapid U.S. spread
Page 1 and 2: ANA-MAINE JOURNAL The Newsletter of
Page 3: May, June, July 2021 ANA Maine Jour
Page 7 and 8: May, June, July 2021 ANA Maine Jour
Page 15: May, June, July 2021 ANA Maine Jour

Maine Journal - May 2021

Create successful ePaper yourself

Delete template?

Save as template?